Back to first-pass browser

First-pass extracted concept

HIF inhibitors

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

direct and indirect HIF inhibitors

Extracted Explainers

What the tool is doing

This label covers direct and indirect therapeutic strategies intended to inhibit HIF signaling in cancer. The abstract names small molecules, peptidomimetics, antibodies, and PROTACs as examples.

Source 1DOIPubMed

What problem it solves

These approaches aim to suppress HIF-linked tumor-promoting processes and improve outcomes when used alone or in combination with other therapies.

Source 1DOIPubMed

What it does not solve

The abstract states that challenges remain, particularly drug resistance, so HIF inhibition is not presented as a complete solution.

Source 1DOIPubMed

Alternatives

The abstract contrasts HIF inhibition with traditional therapies such as chemotherapy or radiation and with immunotherapies, and also discusses combining them.

Source 1DOIPubMed

Evidence Snippets

Direct and indirect HIF inhibitors-including small molecules, peptidomimetics, antibodies, and proteolysis-targeting chimeras (PROTACs)-are under preclinical and clinical evaluation for their therapeutic efficacy.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1combination therapysupports2026Source 1DOIPubMed

Preclinical and early clinical trials have demonstrated significant synergistic effects in inhibiting tumor development when HIF inhibition is combined with chemotherapy, radiation, or immunotherapies.

Claim 2limitationsupports2026Source 1DOIPubMed

Drug resistance remains a challenge for HIF-targeted therapeutic strategies.

Claim 3therapeutic strategysupports2026Source 1DOIPubMed

Direct and indirect HIF inhibitors, including small molecules, peptidomimetics, antibodies, and PROTACs, are under preclinical and clinical evaluation for therapeutic efficacy.